LEGN Stock Summary and Trading Ideas (Legend Biotech - American Depositary Shares | NASDAQ:LEGN)

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.

As of September 18, 2026, LEGN stock price climbed to $17.61 with 2,584,822 million shares trading.

LEGN has a beta of 1.23, meaning it tends to be more sensitive to market movements. LEGN has a correlation of 0.05 to the broad based SPY ETF.

LEGN has a market cap of $3.42 billion. This is considered a Mid Cap stock.

Last quarter Legend Biotech - American Depositary Shares reported $388 million in Revenue and $.16 earnings per share. This beat revenue expectation by $34 million and missed earnings estimates by -$.09.

In the last 3 years, LEGN traded as high as $70.78 and as low as $16.24.

The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, PBE, CANC, EEM.

LEGN has underperformed the market in the last year with a price return of -49.9% while the SPY ETF gained +16.8%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.9% and -18.2%, respectively, while the SPY returned +2.3% and -0.9%, respectively.

LEGN support price is $16.97 and resistance is $18.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.